Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
24.73 ^USD	+4.37%		+3.65%	+85.94%

25.03.	Präsident und CEO von Dyne Therapeutics Joshua Brumm tritt zurück, John Cox wird Nachfolger; Aktien fallen vorbörslich um 7%	MT
25.03.	Dyne Therapeutics, Inc. kündigt Änderungen im Management an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	27.03.
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	27.03.
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	25.03.
Dyne Therapeutics Announces CEO Transition	25.03.
Dyne Therapeutics, Inc. Announces Management Changes	25.03.
Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes	25.03.
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13.03.
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days	13.03.
Dyne Therapeutics Insider Sold Shares Worth $1,398,347, According to a Recent SEC Filing	05.03.
Dyne Therapeutics's Q4 Net Loss Widens; Shares Down Pre-Bell	05.03.
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05.03.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	05.03.
Dyne Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
Dyne Therapeutics Insider Sold Shares Worth $2,895,519, According to a Recent SEC Filing	04.03.
Dyne Therapeutics Insider Sold Shares Worth $811,865, According to a Recent SEC Filing	04.03.
Dyne Therapeutics Insider Sold Shares Worth $357,296, According to a Recent SEC Filing	04.03.
Dyne Therapeutics Insider Sold Shares Worth $19,626,903, According to a Recent SEC Filing	29.02.
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	14.02.
Dyne Therapeutics to Present at February Investor Conferences	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Andere Sprachen

Filter